|
Insurance & Litigation
•
|
Tools & Information
•
•
•
|
|
 Back to Reuters Health News Archives
Reuters Health News: 10-30-2004
WASHINGTON (Reuters) - Novartis AG won U.S. approval to promote the drug Femara for women who have finished standard therapy for early-stage breast cancer and run out of options, the company said on Friday.
WASHINGTON (Reuters) - Twenty-nine patients who took AstraZeneca Plc's AZN.L AZN.N anti-cholesterol drug Crestor have developed kidney damage, a U.S. consumer group said on Friday as it called again for a ban on the medicine.
SEATTLE (Reuters) - A cruise operator ferrying U.S. residents to Canada for flu shots said on Friday it has cut back on its popular service due to overwhelming demand and concerns about diminishing supplies north of the border.
GENEVA (Reuters) - Ducks also spread bird flu, increasing the risk to humans from a virus that has killed 32 people in Thailand and Vietnam this year, the World Health Organization (WHO) said on Friday.
NEW YORK (Reuters Health) - Transplantation of pigment-producing cells called melanocytes appears to be a safe and effective treatment for vitiligo, in which patches of skin lose their coloration, appearing whitish, according to two reports in the Archives of Dermatology.
NEW YORK (Reuters Health) - US researchers describe a man who experienced episodes of painful sweating in the face that occurred spontaneously or when eating certain foods.
NEW YORK (Reuters Health) - Laser therapy and ultrasound promote wound healing, Turkish researchers have shown in animal experiments.
NEW YORK (Reuters Health) - Vulvar dystrophy is a common gynecologic disorder usually involving white lesions on tissues of the vulva that are often accompanied by intense itching. Currently, various treatments can help but may not be long-lasting.
NEW YORK (Reuters Health) - After undergoing prostate removal because of localized cancer, African-American men have better recovery of sexual and urinary function than do non-Hispanic white men, researchers report.
NEW YORK (Reuters) - An experimental Bristol-Myers Squibb Co. pill for the liver disease hepatitis B proved better than a commonly-used anti-viral medicine made by GlaxoSmithKline in late-stage clinical studies, researchers said.
|
|
